Marc Lindner, DO
Pulmonary Disease · Newark, NJNPI 1891138236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations.
Across 406 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Actelion Pharmaceuticals US, Inc.$1K
- Boehringer Ingelheim$681
- United Therapeutics Corporation$584
- Sanofi$505
- Astellas Pharma US Inc$500
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,98297%
- Education$2723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 88 | $1,469 |
| Actelion Pharmaceuticals US, Inc. | 55 | $1,182 |
| Boehringer Ingelheim | 40 | $681 |
| United Therapeutics Corporation | 37 | $584 |
| Sanofi | 21 | $505 |
| Astellas Pharma US Inc | 16 | $500 |
| AstraZeneca(2 entities) | 22 | $437 |
| La Jolla Pharmaceutical Company | 4 | $376 |
| Insmed, Inc. | 27 | $344 |
| Johnson & Johnson(2 entities) | 7 | $246 |
| Merck | 14 | $228 |
| Mylan Specialty L.p. | 13 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $210 |
| Bayer | 11 | $159 |
| Regeneron Healthcare Solutions, Inc. | 3 | $156 |
| Pulmonx Corporation | 3 | $129 |
| CSL Behring | 1 | $125 |
| Shionogi Inc | 1 | $125 |
| Viatris Specialty LLC | 5 | $95 |
| Eurofins Viracor, LLC | 1 | $87 |
| Mallinckrodt Hospital Products Inc. | 4 | $68 |
| Pfizer | 3 | $48 |
| Vifor Pharma, Inc. | 2 | $34 |
| Novo Nordisk | 2 | $33 |
| Kamada Ltd. | 1 | $33 |
| 3b Medical, Inc. | 1 | $31 |
| Akcea Therapeutics, Inc. | 2 | $27 |
| Electromed, Inc. | 1 | $18 |
| Invivyd Inc | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Amgen | 1 | $14 |
| Gilead | 1 | $14 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,254 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Newark
- Richard MillerNewark$328K
- Yazan AbdeenNewark$44K
- Christina MiglioreNewark$27K
- Pratik PatelNewark$16K
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Jason ShatkinParamus$282K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.